BI Aggrenox Recommended For Stroke; Mortality Labeling Uncertain
Executive Summary
FDA will consider whether to include information on the potential mortality benefit of Boehringer-Ingelheim's Aggrenox (dipyridamole/aspirin) in labeling after an advisory committee recommended against including a mortality claim among the approved indications for the product.